Case Report: Multimodal treatment of pediatric H3G34-mutant diffuse hemispheric glioma: a safety and feasibility case report combining precision medicine and tumor treating fields with conventional care
Nov 2026· Frontiers in Oncology· 0 citations· 66 references
TL;DR
A case of a 13-year-old boy with H3G34-DHG who underwent a multimodal treatment strategy, combining backbone chemotherapy, radiotherapy, surgery, tumour treating fields with Wilms Tumour-1 (WT1) directed dendritic cell immunotherapy and targeted therapy (STAT3-inhibition) supports the feasibility of combining multiple therapeutic modalities in the management of high-risk paediatric brain tumours.
Abstract
Diffuse hemispheric glioma, H3G34-mutant (H3G34-DHG) is a rare, highly malignant brain tumour with a dismal prognosis and a median time to progression (TTP) of 10 months with best available practice. We report a case of a 13-year-old boy with H3G34-DHG who underwent a multimodal treatment strategy, combining backbone chemotherapy, radiotherapy, surgery, tumour treating fields with Wilms Tumour-1 (WT1) directed dendritic cell immunotherapy and targeted therapy (STAT3-inhibition). The patient had a TTP of 787 days or 25 months, more than double the literature-reported median, with preserved quality of life and showing downregulation of WT1. This case supports the feasibility of combining multiple therapeutic modalities in the management of high-risk paediatric brain tumours, with potential synergy between different treatment elements. While access to novel therapies in the context of clinical trials remains essential, this case illustrates how treatment can be tailored to individual tumour biology and tolerability. The rationale presented in this detailed case report can inform future trial designs and promote precision medicine approaches for this tumour type.
AIM
To evaluate the clinical and radiological outcomes of upfront temozolomide (TMZ) monotherapy in deferring radiotherapy for multifocal glioblastoma (GBM).
METHODS
We analysed 18 consecutive adult patients with newly diagnosed, multifocal GBM treated with upfront TMZ monotherapy between 2016 and 2024. The primary e...
Chun Khai Loh, H. Wheeler, Adrian Lee et al.· Asia-Pacific Journal of Clin...· 0 citations
Heterogeneity of adult H3 K27-altered DMG is highlighted and patterns of adult H3 K27-altered DMG in cases assessed at autopsy are described in cases assessed at autopsy.
A. Lahrache, H. Reecher, Aleksandra Winiarz et al.· Frontiers in Oncology· 0 citations
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer, characterized by high invasiveness and treatment resistance. Patients with PSC often exhibit poor treatment outcomes, short median survival and a dismal prognosis, necessitating novel comprehensive treatment strategies to address thi...
Zi-Jian Qiu, F. Xuan, Xi-Lan Mao et al.· Oncology Letters· 0 citations
Clinogenomic characterization of diffuse hemispheric glioma presenting pre-operatively with tumor-associated bleeding suggests survival, transcriptional, and mutational differences for pediatric DHG patients presenting with tumor-associated bleeding are suggested.
N. Joshi, Patrick J. Beck, Rakesh A. Murugesan et al.· Cancer Research· 0 citations
INTRODUCTION
Targeted treatment in children, especially with sarcomas, has limited utility due to small numbers of patients with driving mutations. Multimodal combination treatment and patient-centered approach combine treatment modalities administered based on comprehensive biological and empirical factors. Together,...
M. Kyr, K. Polaskova, P. Múdry et al.· Oncology and Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.